Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
TILADE (nedocromil sodium) is a metered-dose aerosol inhaler approved in 1992 for asthma management. It functions as a prophylactic anti-inflammatory agent used to reduce airway hyperresponsiveness and asthma symptoms. The drug is administered via inhalation to deliver medication directly to the respiratory tract.
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30/100), the brand team is likely focused on cost management and transitional planning rather than expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
TILADE roles are primarily commercial and legacy-focused, with minimal new career opportunities emerging from this product line. Professionals assigned to TILADE should expect responsibility for managing declining volumes and maintaining market share against generic/biosimilar threats rather than driving growth.
Worked on TILADE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.